Precision BioSciences

Company Overview

Precision Bio Sciences is a genome editing company located in Durham, N.C. The company is to translate the powerful genome editing technology into greatly needed products throughout the life sciences. Precision Biosciences is an advanced gene editing company leveraging its unique proprietary ARCUS platform to create in vivo gene editing therapies for complex gene modifications, including gene elimination, insertion, and excision. ARCUS stands out as the sole gene editor exclusively derived from a protein known as a homing endonuclease, which evolved naturally to edit genomes and add functionality safely. ARCUS excels in achieving precise outcomes due to its predominant use of homology-directed repair (HDR) rather than non-homologous end joining (NHEJ).

The company developed ARCUS, a proprietary genome editing technology platform. ARCUS is based on I-CreI, a naturally occurring genome editing enzyme, which belongs to mega nucleases family. Precision’s pipeline includes multiple allogeneic CAR-T immunotherapies in early-stage and a few in vivo gene editing products in late-stage preclinical development. The company expects to submit the IND for PBGENE-HBV (Elimination) and or CTA in 2024.

Financial Highlights (FY 2023)

Company's Business Segments

• Gene Editing : This segement helps in making highly specific changes in a DNA sequence of a living organism.